featured
The First Trial of CIM331, a Humanized Anti-Human IL-31 Receptor A Antibody
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The First Trial of CIM331, a Humanized Anti-Human IL-31 Receptor A Antibody, for Healthy Volunteers and Patients With Atopic Dermatitis to Evaluate Safety, Tolerability and Pharmacokinetics of a Single Dose in a Randomised, Double-Blind, Placebo-Controlled Study
Br J Dermatol 2015 Sep 26;[EPub Ahead of Print], O Nemoto, M Furue, H Nakagawa, M Shiramoto, R Hanada, S Matsuki, S Imayama, M Kato, I Hasebe, K Taira, M Yamamoto, R Mihara, K Kabashima, T Ruzicka, J Hanifin, Y KumagaiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.